@article{17826a78f9e04794a2be14d46a89a769,
title = "Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project",
author = "Hess, {Paul L.} and Kevin Kennedy and Michael Cowherd and Virani, {Salim S.} and Masoudi, {Frederick A.} and Navar, {Ann Marie} and Yeh, {Robert W.} and Ho, {P. Michael} and Maddox, {Thomas M.}",
note = "Funding Information: This research was supported by the American College of Cardiology National Cardiovascular Data Registry . The PINNACLE Registry is an initiative of the American College of Cardiology. Bristol-Myers Squibb and Pfizer Inc are founding sponsors of the PINNACLE Registry. The PINNACLE Registry and the National Cardiovascular Data Registry had no role in the design or conduct of the study, the management or analysis performed in the study, or the interpretation of the data. Dr Masoudi is the Chief Medical Officer for the NCDR. Dr. Navar is supported by the National Heart, Lung, and Blood Institute (K01HL133416), and reports research support from Regeneron/Sanofi, and Amgen, Inc., and support as a consultant for Sanofi and Amgen, Inc. Other authors have no relevant disclosures.",
year = "2018",
month = jan,
doi = "10.1016/j.ahj.2017.09.004",
language = "English (US)",
volume = "195",
pages = "151--152",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
}